City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 822,840 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average trading volume of 361,905 shares, the short-interest ratio is currently 2.3 days.
Insider Activity
In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the purchase, the insider directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert Nelsen purchased 170,000 shares of the company’s stock in a transaction on Monday, October 19th. The shares were bought at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the transaction, the director directly owned 13,692,507 shares of the company’s stock, valued at $246,465,126. This represents a 1.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
City Therapeutics Stock Down 6.2%
Shares of CTY opened at $16.98 on Tuesday. City Therapeutics has a 12 month low of $15.81 and a 12 month high of $23.88.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Wall Street Zen raised shares of City Therapeutics to a “hold” rating in a research note on Saturday, October 24th. Zacks Research started coverage on City Therapeutics in a research note on Wednesday, November 11th. They set a “hold” rating on the stock. Jefferies Financial Group began coverage on City Therapeutics in a report on Monday. They set a “strong-buy” rating on the stock. Stifel Nicolaus started coverage on City Therapeutics in a research report on Tuesday, November 10th. They issued a “buy” rating and a $34.00 price objective for the company. Finally, Oppenheimer began coverage on City Therapeutics in a research report on Tuesday, November 10th. They issued an “outperform” rating and a $46.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, City Therapeutics presently has a consensus rating of “Buy” and an average price target of $37.33.
Get Our Latest Research Report on CTY
About City Therapeutics
City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.
See Also
- Five stocks we like better than City Therapeutics
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
